Denali Therapeutics/$DNLI
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Denali Therapeutics
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegeneration disease. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, DNL747, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others.
Ticker
$DNLI
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
443
ISIN
US24823R1059
Website
DNLI Metrics
BasicAdvanced
$2.1B
-
-$2.67
1.33
-
Price and volume
Market cap
$2.1B
Beta
1.33
52-week high
$31.56
52-week low
$10.57
Average daily volume
1.6M
Financial strength
Current ratio
9.563
Quick ratio
8.921
Long term debt to equity
3.567
Total debt to equity
4.332
Interest coverage (TTM)
-1,030.41%
Profitability
EBITDA (TTM)
-513.951
Effective tax rate (TTM)
-0.01%
Management effectiveness
Return on assets (TTM)
-22.58%
Return on equity (TTM)
-35.21%
Valuation
Price to book
1.88
Price to tangible book (TTM)
1.88
Price to free cash flow (TTM)
-6.423
Free cash flow yield (TTM)
-15.57%
Free cash flow per share (TTM)
-226.20%
Growth
Earnings per share change (TTM)
173.65%
3-year earnings per share growth (CAGR)
4.47%
What the Analysts think about DNLI
Analyst ratings (Buy, Hold, Sell) for Denali Therapeutics stock.
Bulls say / Bears say
Denali Therapeutics' lead candidate, tividenofusp alfa (DNL310), received FDA Breakthrough Therapy Designation for Hunter syndrome, indicating strong potential for accelerated approval and market entry. (globenewswire.com)
Analysts have shown confidence in Denali's prospects, with Baird initiating coverage with an 'Outperform' rating and a $31 price target, suggesting significant upside potential. (nasdaq.com)
Denali maintains a robust cash position of $1.2 billion as of December 2024, providing financial stability to advance its pipeline and commercial initiatives. (panabee.com)
Denali reported a net loss of $423 million in 2024, a significant increase from the $145 million loss in 2023, raising concerns about financial sustainability. (panabee.com)
The company halted its Phase 2 multiple sclerosis study of oditrasertib (SAR443820/DNL788) due to failure to meet primary and key secondary endpoints, indicating potential challenges in its clinical pipeline. (investing.com)
Denali underwent a reorganization, including layoffs and spinning off its preclinical small molecule portfolio, which may signal internal challenges and strategic shifts. (fiercebiotech.com)
Data summarised monthly by Lightyear AI. Last updated on 8 Jul 2025.
DNLI Financial Performance
Revenues and expenses
DNLI Earnings Performance
Company profitability
DNLI News
AllArticlesVideos
Denali Therapeutics Announces FDA Acceptance and Priority Review of Biologics License Application (BLA) for Tividenofusp Alfa for Hunter Syndrome (MPS II)
GlobeNewsWire·2 weeks ago
Denali Therapeutics Reports First Quarter 2025 Financial Results and Business Highlights Including Completion of BLA Rolling Submission for Tividenofusp Alfa for Hunter Syndrome
GlobeNewsWire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Denali Therapeutics stock?
Denali Therapeutics (DNLI) has a market cap of $2.1B as of July 18, 2025.
What is the P/E ratio for Denali Therapeutics stock?
The price to earnings (P/E) ratio for Denali Therapeutics (DNLI) stock is 0 as of July 18, 2025.
Does Denali Therapeutics stock pay dividends?
No, Denali Therapeutics (DNLI) stock does not pay dividends to its shareholders as of July 18, 2025.
When is the next Denali Therapeutics dividend payment date?
Denali Therapeutics (DNLI) stock does not pay dividends to its shareholders.
What is the beta indicator for Denali Therapeutics?
Denali Therapeutics (DNLI) has a beta rating of 1.33. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.